Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma

Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6.

Abstract

Vismodegib is the first Hedgehog pathway inhibitor to be approved in the USA, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. In an ongoing, noncomparative, phase II trial, oral vismodegib was effective in and had an acceptable tolerability profile in the treatment of patients with locally advanced or metastatic BCC.

MeSH terms

  • Adult
  • Anilides / adverse effects
  • Anilides / pharmacology
  • Anilides / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / pathology
  • Drug Approval
  • Hedgehog Proteins / antagonists & inhibitors
  • Humans
  • Neoplasm Metastasis
  • Pyridines / adverse effects
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology

Substances

  • Anilides
  • Antineoplastic Agents
  • Hedgehog Proteins
  • HhAntag691
  • Pyridines